SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Moxifloxacin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Innishannon
   County Cork - Ireland
   Telephone : 353 214329300
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

   Additional Labelling
   EUH210 Safety data sheet available on request.

2.3 Other hazards
   None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration</th>
</tr>
</thead>
</table>


SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Moxifloxacin Liquid Formulation

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
Hazardous combustion products: No hazardous combustion products are known

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions
Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Moxifloxacin Liquid Formulation

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Avoid inhalation of vapour or mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin HCl</td>
<td>186826-86-8</td>
<td>TWA</td>
<td>1000 µg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment
Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties
Appearance : liquid
Colour : yellow
Odour : odourless
Odour Threshold : No data available
pH : 4.1 - 4.6
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
### Moxifloxacin Liquid Formulation

**Relative vapour density** : No data available  
**Relative density** : No data available  
**Density** : 1.0044 g/cm³ (20 °C)  
**Solubility(ies)**  
- **Water solubility** : slightly soluble  
- **Partition coefficient: n-octanol/water** : No data available  
- **Auto-ignition temperature** : No data available  
- **Decomposition temperature** : No data available  
**Viscosity**  
- **Viscosity, kinematic** : No data available  
**Explosive properties** : Not explosive  
**Oxidizing properties** : The substance or mixture is not classified as oxidizing.

**9.2 Other information**  
- **Flammability (liquids)** : No data available  
- **Molecular weight** : No data available  
- **Particle size** : No data available

### SECTION 10: Stability and reactivity

**10.1 Reactivity**  
Not classified as a reactivity hazard.

**10.2 Chemical stability**  
Stable under normal conditions.

**10.3 Possibility of hazardous reactions**  
Hazardous reactions : Can react with strong oxidizing agents.

**10.4 Conditions to avoid**  
Conditions to avoid : None known.

**10.5 Incompatible materials**  
Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**  
No hazardous decomposition products are known.
**SECTION 11: Toxicological information**

**11.1 Information on toxicological effects**

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:**

- **Moxifloxacin HCL:**
  - Acute oral toxicity: LD50 (Rat): 1,320 mg/kg
  - LD50 (Mouse): > 435 mg/kg
  - LD50 (Monkey): 1,500 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

- **Moxifloxacin HCL:**
  - Species: Rabbit
  - Result: No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:**

- **Moxifloxacin HCL:**
  - Species: Rabbit
  - Result: Moderate eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:**

- **Moxifloxacin HCL:**
  - Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: in vitro micronucleus test
Result: negative

Genotoxicity in vivo
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Moxifloxacin HCL:

Effects on fertility
Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 500 mg/kg body weight
Result: Effects on fertility

Effects on foetal development
Test Type: Embryo-foetal development
Species: Monkey
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: negative

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 20 mg/kg body weight
Symptoms: Skeletal malformations

Reproductive toxicity - Assessment
Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.
Moxifloxacin Liquid Formulation

Components:

Moxifloxacin HCL:
Target Organs: Liver
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:
Species: Rat
LOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 4 Weeks

Species: Rat
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Liver
Symptoms: Liver disorders

Species: Rat
NOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Liver
Symptoms: Liver disorders

Species: Monkey
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 4 Weeks
Symptoms: No adverse effects

Species: Monkey
NOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Gastrointestinal tract
Symptoms: Vomiting

Species: Monkey
Application Route: Oral
Exposure time: 26 Weeks
Target Organs: Liver
Symptoms: Liver disorders

Aspiration toxicity
Not classified based on available information.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Moxifloxacin Liquid Formulation

Experience with human exposure

Components:

Moxifloxacin HCL:
Ingestion: Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good
Moxifloxacin Liquid Formulation

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
REACH - List of substances subject to authorisation (Annex XIV)
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer
Regulation (EC) No 850/2004 on persistent organic pollutants
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)
Not applicable

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302: Harmful if swallowed.
H319: Causes serious eye irritation.
H361d: Suspected of damaging the unborn child.
H373: May cause damage to organs through prolonged or repeated
Moxifloxacin Liquid Formulation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GNP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISQ - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure - Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their exposure.

Full text of other abbreviations

| Acute Tox. | : | Acute toxicity |
| Eye Irrit. | : | Eye irritation |
| Repr. | : | Reproductive toxicity |
| STOT RE | : | Specific target organ toxicity - repeated exposure |
intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN